Abstract
Compelling evidence suggests that cognitive function is strongly influenced by genetics. Here, we conduct a large-scale exome study to examine whether rare protein coding variants impact cognitive function in the adult population (N=485,930). We identify eight genes associated with adult cognitive function through rare coding variants with large effects. We demonstrate how the dosage of a single gene, KDM5B, may determine the variability of cognitive, behavioral, and molecular traits in mice and humans. We further provide evidence that rare and common variants overlap in association signals and contribute additively to cognitive function. Our findings uncover a contribution of rare coding variants to cognitive function and highlight that the spectrum of cognitive function in the normal adult population is influenced by the action of single genes.
Competing Interest Statement
C.-Y.C., T.F., E.T., H.R., and members of the Biogen Biobank Team are employees of Biogen. J.Z.L. is an employee of GlaxoSmithKline. R.T. is an employee of Dewpoint Therapeutics. M.E.H. is a co-founder, shareholder, non-executive director of Congenica, and an advisor to Astra-Zeneca.
Funding Statement
UK Biobank Exome Sequencing Consortium (AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, Pfizer, Regeneron and Takeda) for generation the whole exome sequencing data. Chia-Yen Chen, Terry Fang, Ellen A. Tsai, Heiko Runz, and members of the Biogen Biobank Team are employees of Biogen. Ruoyu Tian is an employee of Dewpoint Therapeutics. Jimmy Z. Liu is an employee of GlaxoSmithKline.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of UK Biobank data in the current study is approved under application #26041. The use of Mass General Brigham Biobank, the SUPER-Finland study, and the Northern Finland Intellectual Disability (NFID) study in this work were under the approval of each respective IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
